Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options

doi:10.1086/596737

Editorial

. 2009 Mar 1;199(5):610-2.

doi: 10.1086/596737.

Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options

Robert W Shafer

PMID: 19210160
PMCID: PMC4764065
DOI: 10.1086/596737

Editorial

Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options

Robert W Shafer. J Infect Dis. 2009.

. 2009 Mar 1;199(5):610-2.

doi: 10.1086/596737.

Author

Robert W Shafer

PMID: 19210160
PMCID: PMC4764065
DOI: 10.1086/596737

No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: R.W.S. has consulted for Bristol-Myers Squibb, Celera, and Siemens Health Care. He has received speaking honoraria from Gilead Sciences and research funding from Abbott Laboratories, Bristol Myers Squibb, Celera, and Gilead Sciences. He has an ongoing research collaboration with 454 Life Sciences–Roche Diagnostics.

Comment on

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ; Terry Beirn Community Programs for Clinical Research on AIDS. Simen BB, et al. J Infect Dis. 2009 Mar 1;199(5):693-701. doi: 10.1086/596736. J Infect Dis. 2009. PMID: 19210162 Clinical Trial.

Cited by

Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.
Zhou Z, Tang K, Zhang G, Wadonda-Kabondo N, Moyo K, Rowe LA, DeVos JR, Wagar N, Zheng DP, Guo H, Nkengasong J, Frace M, Sammons S, Yang C. Zhou Z, et al. Afr J Lab Med. 2018 May 30;7(1):708. doi: 10.4102/ajlm.v7i1.708. eCollection 2018. Afr J Lab Med. 2018. PMID: 29977795 Free PMC article.
Lower genetic variability of HIV-1 and antiretroviral drug resistance in pregnant women from the state of Pará, Brazil.
Machado LF, Costa IB, Folha MN, da Luz AL, Vallinoto AC, Ishak R, Ishak MO. Machado LF, et al. BMC Infect Dis. 2017 Apr 12;17(1):270. doi: 10.1186/s12879-017-2392-y. BMC Infect Dis. 2017. PMID: 28403828 Free PMC article.
Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY® System.
Cheung KW, Peng Q, He L, Cai K, Jiang Q, Zhou B, To SW, Yam WC, Liu L, Chen Z, Wang H. Cheung KW, et al. PLoS One. 2016 Apr 19;11(4):e0153641. doi: 10.1371/journal.pone.0153641. eCollection 2016. PLoS One. 2016. PMID: 27092551 Free PMC article.
Prevalence of WHO transmitted drug resistance mutations by deep sequencing in antiretroviral-naïve subjects in Hunan Province, China.
Xiaobai Z, Xi C, Tian H, Williams AB, Wang H, He J, Zhen J, Chiarella J, Blake LA, Turenchalk G, Kozal MJ. Xiaobai Z, et al. PLoS One. 2014 Jun 4;9(6):e98740. doi: 10.1371/journal.pone.0098740. eCollection 2014. PLoS One. 2014. PMID: 24896087 Free PMC article.
Base-calling algorithm with vocabulary (BCV) method for analyzing population sequencing chromatograms.
Fantin YS, Neverov AD, Favorov AV, Alvarez-Figueroa MV, Braslavskaya SI, Gordukova MA, Karandashova IV, Kuleshov KV, Myznikova AI, Polishchuk MS, Reshetov DA, Voiciehovskaya YA, Mironov AA, Chulanov VP. Fantin YS, et al. PLoS One. 2013;8(1):e54835. doi: 10.1371/journal.pone.0054835. Epub 2013 Jan 28. PLoS One. 2013. PMID: 23382983 Free PMC article.

See all "Cited by" articles

References

1. Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr. 2006;42:610–3. - PubMed
1. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A. 2006;103:7094–9. - PMC - PubMed
1. Cai F, Chen H, Hicks CB, Bartlett JA, Zhu J, Gao F. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods. 2007;4:123–5. - PubMed
1. Beck IA, Crowell C, Kittoe R, et al. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J Acquir Immune Defic Syndr. 2008;48:418–27. - PMC - PubMed
1. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008;5:e158. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations
Medical
- Genetic Alliance
- MedlinePlus Health Information

[1] Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr. 2006;42:610–3. - PubMed

[2] Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr. 2006;42:610–3. - PubMed

[3] Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A. 2006;103:7094–9. - PMC - PubMed

[4] Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A. 2006;103:7094–9. - PMC - PubMed

[5] Cai F, Chen H, Hicks CB, Bartlett JA, Zhu J, Gao F. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods. 2007;4:123–5. - PubMed

[6] Cai F, Chen H, Hicks CB, Bartlett JA, Zhu J, Gao F. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods. 2007;4:123–5. - PubMed

[7] Beck IA, Crowell C, Kittoe R, et al. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J Acquir Immune Defic Syndr. 2008;48:418–27. - PMC - PubMed

[8] Beck IA, Crowell C, Kittoe R, et al. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J Acquir Immune Defic Syndr. 2008;48:418–27. - PMC - PubMed

[9] Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008;5:e158. - PMC - PubMed

[10] Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008;5:e158. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options

Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options

Author

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical